In WFHC on Strong NEWS out...3yr Agreement...
By: respect98
21 May 2003, 01:27 PM EDT Msg. 242574 of 242598
Jump to msg. #
re:WFHC NEWS: Women First Signs Three-Year Agreement With Premier for Product Line Availability to Nearly 1,500 Hospitals
Wednesday May 21, 7:00 am ET
SAN DIEGO--(BUSINESS WIRE)--May 21, 2003--Women First HealthCare, Inc. (NASDAQ:WFHC - News) announced today that it has signed a nationwide agreement with the group purchasing arm of Premier Inc. Under the terms of the agreement, products in the Women First HealthCare portfolio will be available to nearly 1,500 hospitals and other healthcare sites that use Premier as their key contracting and purchasing resource.
Under this three-year agreement, Women First HealthCare will be offering a wide variety of pharmaceutical products including drugs to address menopausal hot flashes, post-procedural pain and unwanted facial hair. Women First HealthCare specializes in products designed for women over 40 nearing or experiencing menopause. Esclim(TM), the company's transdermal estradiol system, is included as part of the agreement. Esclim relieves symptoms attributed to blood vessel dilation, such as hot flashes and night-sweats, caused by estrogen loss after removal of the ovaries. Additional products will include pharmaceuticals for pain and headache management.
Some of the country's best-known not-for-profit hospitals will have access to Women First HealthCare products. "Women First HealthCare is pleased to add Premier to its growing list of pharmaceutical partners. Working through a 1,500-member GPO is a crucial step toward expanding the presence of our products in the marketplace," stated Saundra L. Childs, Women First HealthCare Vice President of the Pharmaceutical Division. "With an estimated 600,000 hysterectomies performed annually in the U.S., we are especially pleased that Esclim can now be prescribed to women immediately post-hysterectomy, and continued after discharge from the hospital."
biz.yahoo.com
(Voluntary Disclosure: Position- Long; ST Rating- Strong Buy; LT Rating- Strong Buy) |
